Small-sample behavior of novel phase I designs: Rejoinder

Oron AP . Up-and-Down and the Percentile-Finding Problem. University of Washington, Seattle, WA, 2007. Available at: http://arxiv.org/abs/0808.3004

Resche-Rigon M Zohar S Chevret S . Adaptive designs for dose-finding in non-cancer phase II trials: Influence of early unexpected outcomes. Clin Trials 2008; 5: 595–606.

Lee SM Cheung YK . Model calibration in the continual reassessment method. Clin Trials 2009; 6: 227–38.

Neuenschwander B Branson M Gsponer T . Critical aspects of the Bayesian approach to phase I cancer trials. Stat Med 2008; 27: 2420–39.

Azriel D . A note on the robustness of the continual reassessment method. Stat Probabil Lett 2012; 82: 902–06.

Oron AP Azriel D Hoff PD . Dose-finding designs: The role of convergence properties. Int J Biostat 2011; 7(1): Article 39.

Durham SD Flournoy N . Up-and-down designs. I Stationary treatment distributions. In Flournoy N Rosenberger WF (eds) Adaptive Designs, vol. 25 of IMS Lecture Notes Monograph Series. Institute of Mathematical Statistics, Hayward, CA, 1995, pp. 139–57.

Rogatko A Schoeneck D Jonas W . Translation of innovative designs into phase I trials. J Clin Oncol 2007; 25(31): 4982–86.

Mathew P Thall PF Jones D . Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: A modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 2004; 22(16): 3323–29.